[(2S,4R)-4-(4-Acetamido-2-oxopyrimidin-1(2H)-yl)-1,3-dioxolan-2-yl]methyl benzoate | 145414-64-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: [(2S,4R)-4-(4-Acetamido-2-oxopyrimidin-1(2H)-yl)-1,3-dioxolan-2-yl]methyl benzoate
• 英文别名: [(2S,4R)-4-(4-acetamido-2-oxopyrimidin-1-yl)-1,3-dioxolan-2-yl]methyl benzoate
• CAS: 145414-64-8
• 化学式: C₁₇H₁₇N₃O₆
• 分子量: 359.338
• InChiKey: BAODLFFHZLIRKZ-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [(2S,4R)-4-(4-Acetamido-2-oxopyrimidin-1(2H)-yl)-1,3-dioxolan-2-yl]methyl benzoate 在 氨 作用下， 以 甲醇 为溶剂， 生成 拉米夫定相关化合物(Α-TROXACITABINE)
  参考文献：
  名称：

  Potent anti-HIV and anti-HBV activities of (−)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric syntheses.

  摘要：

  The asymmetric syntheses of (+)-L-beta-dioxolane-T and (-)-L-beta-dioxolane-C were accomplished starting from 1,6-anhydro-L-beta-gulopyranose, and their anti-HIV and anti-HBV activities were evaluated in human PBM cells, CEM cells and 2.2.15 cells, respectively.

  DOI：

  10.1016/s0040-4039(00)60890-0
• 作为产物：
  描述：

  (2S,4S)-2-[(Benzoyloxy)methyl]-1,3-dioxolane-4-carboxylic acid 在 三氟甲磺酸三甲基硅酯 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 生成 [(2S,4R)-4-(4-Acetamido-2-oxopyrimidin-1(2H)-yl)-1,3-dioxolan-2-yl]methyl benzoate
  参考文献：
  名称：

  Potent anti-HIV and anti-HBV activities of (−)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric syntheses.

  摘要：

  The asymmetric syntheses of (+)-L-beta-dioxolane-T and (-)-L-beta-dioxolane-C were accomplished starting from 1,6-anhydro-L-beta-gulopyranose, and their anti-HIV and anti-HBV activities were evaluated in human PBM cells, CEM cells and 2.2.15 cells, respectively.

  DOI：

  10.1016/s0040-4039(00)60890-0

文献信息

• Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties
  申请人：BioChem Pharma Inc.

  公开号：US20030087918A1

  公开（公告）日：2003-05-08

  Disclosed are compounds of the formula wherein R 1 is hydrogen or an acyl group having 1 to 16 carbon atoms; R 2 is a purine or pyrimidine base or an analogue or derivative thereof; Z is O, S, S═O or SO 2 ; and pharmaceutically acceptable derivatives thereof. Also described are processes for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.

  本发明涉及的化合物的通式为其中R1为氢或具有1至16个碳原子的酰基；R2为嘌呤或嘧啶碱基或其类似物或衍生物；Z为O、S、S═O或SO2；以及其药学上可接受的衍生物。本发明还描述了用于制备这些化合物的过程和中间体、含有这些化合物的制药组合物以及这些化合物在哺乳动物的抗病毒治疗中的使用。
• Potent anti-HIV and anti-HBV activities of (−)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric syntheses.
  作者：Hea O. Kim、Kirupathevy Shanmuganathan、Antonio J. Alves、Lak S. Jeong、J. Warren Beach、Raymond F. Schinazi、Chang Chien-Neng、Cheng Yung-Chi、Chung K. Chu

  DOI：10.1016/s0040-4039(00)60890-0

  日期：1992.11

  The asymmetric syntheses of (+)-L-beta-dioxolane-T and (-)-L-beta-dioxolane-C were accomplished starting from 1,6-anhydro-L-beta-gulopyranose, and their anti-HIV and anti-HBV activities were evaluated in human PBM cells, CEM cells and 2.2.15 cells, respectively.